Cancer Drug Kills Every Kind of Tumor: Study

Thursday, 28 Mar 2013 10:11 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Stanford University scientists have discovered a single drug that has killed or shrunk every kind of cancer tumor it has been used against — a new anti-cancer weapon that some have described as a kind of medical Holy Grail.
 
The drug blocks a protein produced in large amounts by cancer cells — called CD47 — that keeps the body’s immune system from fighting tumors. By shutting down the CD47 production, the new antibody drug effectively leaves cancer cells vulnerable to the body’s own natural defense mechanisms.

Special:
This Small Group of Doctors are Quietly Curing Cancer
 
Tests of the drug found that it destroyed several kinds of human cancer cells transplanted into mice — including breast, ovary, colon, bladder, brain, liver, and prostate tumors — by prompting the rodents’ immune systems to kill the cancer cells.
 
“We showed that even after the tumor had taken hold, the antibody can either cure the tumor or slow its growth and prevent metastasis,” said biologist Irving Weissman of the Stanford University School of Medicine, in an interview with Science Magazine.
 
The research, published this week in the Proceedings of the National Academy of Sciences, could lead to clinical trials in cancer patients as early as next year, according to a Stanford School of Medicine statement posted on its website.
 
The new research is an outgrowth of previous studies Weissman conducted that found leukemia cells produce higher levels of CD47 than healthy cells, Science Magazine reported. In recent years, Weissman and colleagues discovered that blocking CD47 with an antibody cured some cases of lymphoma and leukemia in mice by stimulating the immune system to see the cancer cells as invaders.
 
But the new research goes further, suggesting CD47 isn’t just important against leukemias and lymphomas, but attacks every kind of tumor tested to date, Weissman said.
 
The study was funded, in part, by a $20 million grant from the California Institute for Regenerative Medicine for human studies.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Are Generic Drugs Dangerous?

Tuesday, 23 Sep 2014 09:50 AM

Generic drugs have long been promoted as cost-effective alternatives to brand-name meds. But widespread manufacturing ir . . .

Women Should Be Screened for 'Silent' STDs: Task Force

Tuesday, 23 Sep 2014 08:01 AM

All sexually active women should be screened for two of the most common sexually transmitted infections: chlamydia and g . . .

Plane Travel After Heart Attack Is Safe: Study

Monday, 22 Sep 2014 17:11 PM

People who have a heart attack while traveling abroad may be able to safely fly home on a regular commercial flight, acc . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved